Eli Lilly expands collaboration with Camurus to include amylin agonists
· seekingalpha.com
Eli Lilly expands Camurus FluidCrystal licensing deal for amylin receptor agonists, triggering a $5M payment. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...